Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]
Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
Citation Manager Formats
Make Comment
See Comments

RATIONALE FOR RETIREMENT
The 2012 AAN guideline “Evidence-based guideline update: NSAIDS and other complementary treatments for episodic migraine prevention in adults” has been retired by the AAN Board of Directors on September 16, 2015, due to serious safety concerns with a preventative treatment, butterbur, recommended by this guideline. The recommendations and conclusions in all retired guidelines are considered no longer valid and no longer supported by the AAN. Retired guidelines will remain available on our website for reference use only. If you would like more information on this guideline or the guideline process, please email guidelines{at}aan.com.
- Copyright © 2012 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
- Response to Dr. Mauskopf
- Starr Holland, Armstrong Atlantic State University, Savannah, GAguidelines@aan.com
- Stephen D. Silberstein, Philadelphia, PA; Frederick Freitag, Dallas, TX; David W. Dodick, Scottsdale, AZ; Charles Argoff, Albany, NY
Submitted August 28, 2012 - Safety of Petasites (butterbur)
- Alexander Mauskop, Director, New York Headache Centerdrmauskop@nyheadache.com
- New York, NY
Submitted July 25, 2012
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Special Articles
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adultsReport of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache SocietyS.D. Silberstein, S. Holland, F. Freitag et al.Neurology, April 23, 2012 -
Correction
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Societyet al.Neurology, February 25, 2013 -
In Focus
Spotlight on the April 24 IssueRobert A. Gross et al.Neurology, April 23, 2012 -
What's Happening
What's happening in Neurology®et al.Neurology, November 18, 2019